Genaissance said this week that it intends to create a companion diagnostic test to guide therapy in a collaboration with Japanese pharmaceutical company Sankyo.

"It fits very nicely into the company that Genaissance is going to be acquired by â€" Clinical Data," Jerry Vovis, executive vice president and chief technology officer of Genaissance told Pharmacogenomics Reporter. "One of the reasons that they saw value in Genaissance is that they were looking for the next generation of diagnostic tests."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.